NCT00923351 - Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 2, 2007

Primary Completion Date

August 30, 2012

Study Completion Date

May 15, 2018

Conditions

NeuroblastomaSarcomaRhabdomyosarcoma-EmbryonalRhabdomyosarcoma- AlveolarNeuroectodermal Tumors, Primitive, Peripheral

Interventions

DRUG

Tumor Purged/CD25 Depleted Lymphocytes

BIOLOGICAL

Tumor Purged/CD25 Depleted Lymphocytes with Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine

Tumor lysate/KLH pulsed dendritic cells (minimum of 1 X 10e6 cells/kg) on Day2.

DRUG

rhIL-7

rhIL-7 (20 mcg/kg/dose SQ) approx. 48 hours prior to vaccine) Day 0, Day 14, Day 28 and Day 42

BIOLOGICAL

Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine

Tumor lysate/KLH Pulsed dendritic cell vaccine (1-5 X 10e7 cells/injection site, given in 3 sites intradermal) on Day 2, Day 16, Day 30, Day 44, Day 56, Day 70.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH